ఎముక మజ్జ యొక్క కణితి (సాధారణంగా ప్రాణాంతకం),

Noun:

మైలోనా,

myelomas's Usage Examples:

Bortezomib was also evaluated together with other drugs for the treatment of multiple myelomas in adults.

Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Possible pathologic causes include anemia, myelofibrosis, thalassemia, miliary tuberculosis, cancers involving bone marrow (myelomas, leukemias.

thalassemia, miliary tuberculosis, cancers involving bone marrow (myelomas, leukemias, lymphomas), and in chronic hypoxemia.

SK"F106615) is a substance being studied in the treatment of certain multiple myelomas and other advanced cancers.

52%, 21%, and 16%, respectively, of all multiple myeloma cases; these myelomas are associated with various types of chromosomal aberrancies and mutations.

[citation needed] In preclinical studies with human lymphomas and myelomas, both naked Milatuzumab and the Milatuzumab conjugated with doxorubicin.

For example, the FBXW7 substrate C/EBPα suppresses AML and multiple myelomas require constitutive NF-κB signaling; therefore, disruption of FBXW7-mediated.

also evaluated together with other drugs for the treatment of multiple myelomas in adults.

cases; these myelomas are associated with various types of chromosomal aberrancies and mutations.

myelofibrosis, thalassemia, miliary tuberculosis, cancers involving bone marrow (myelomas, leukemias, lymphomas), and in chronic hypoxemia.

numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for.

PEG is used to fuse two different types of cells, most often B-cells and myelomas in order to create hybridomas.